May 4, 2023 09:00 AM EDTUpdated 03:48 PM
Financing
Startups
Deals

Re­verse merg­ers say hey as biotechs trade low, hunt for al­ter­na­tives and launch few IPOs

Kyle LaHucik

Senior Reporter

The re­verse merg­er an­nounced Wednes­day morn­ing be­tween Ma­gen­ta Ther­a­peu­tics and pri­vate­ly-held Di­anthus Ther­a­peu­tics, which will take over the Nas­daq spot and push for­ward its com­ple­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times